Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

PURPOSE: The combination of gemcitabine plus bevacizumab produced a 21% response rate and a median survival of 8.8 months in a multicenter phase II trial in patients with metastatic pancreatic cancer. These encouraging data led Cancer and Leukemia Group B (CALGB) to conduct a double-blind, placebo-c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kindler, Hedy Lee, Niedzwiecki, Donna, Hollis, Donna, Sutherland, Susan, Schrag, Deborah, Hurwitz, Herbert, Innocenti, Federico, Mulcahy, Mary Frances, O'Reilly, Eileen, Wozniak, Timothy F., Picus, Joel, Bhargava, Pankaj, Mayer, Robert J., Schilsky, Richard L., Goldberg, Richard M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2010
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917317/
https://ncbi.nlm.nih.gov/pubmed/20606091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.28.1386
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky